Webcast Activity

Release date: May 2011
Expiration date: May 30, 2012
Estimated time to complete activity: 1.25 hours

Monograph Activity

Release date: June 2011
Expiration date: June 30, 2012
Estimated time to complete activity: 1.00 hours

Please note: completion of both activities is not required to receive credit. Please choose the activity that best suits your learning preference.

Overview

These programs will discuss effective strategies for the management of chronic pain that reduce the risk of opioid misuse, abuse, and diversion. Faculty panel members will discuss the consequences of inadequate pain relief, potential barriers to provision of adequate pain relief, and strategies to overcome these barriers. One key barrier to be addressed is the fear of opioid abuse, misuse, and diversion. Attendees will be provided with the latest published data regarding risk management strategies and opioid formulations for chronic pain that are designed to deter abuse and misuse.

Target Audience

These activities have been designed to meet the educational needs of pain specialists, addiction medicine specialists, and other healthcare professionals involved in the management of patients with chronic pain.

Learning Objectives

Upon completion of these educational activities, participants should be better able to:

• Describe the causes of inadequate treatment of chronic pain
• Discuss the consequences of inadequately treated pain
• Use a best-practice approach to patient care that includes a pain management plan, risk assessment, and careful monitoring
• Describe pharmacologic therapies that offer clinicians an approach to reduce the risk of opioid abuse

Physician Continuing Education

Accreditation Statement

The Postgraduate Institute for Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Webcast Activity

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™.

Monograph Activity

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of these activities to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Bill H. McCarberg, MD
Speaker: Abbott, Cephalon, Endo Pharmaceuticals, Forest Pharmaceuticals, King Pharmaceuticals, Ligand Pharmaceuticals, Lilly, Merck & Co, Mylan, NeurogesX, Pfizer, PriCara, Purdue Pharma LP

Lynn R. Webster, MD
Consultant/Advisory Board: AstraZeneca, BioDelivery Sciences International, Boston Scientific, Cephalon, Covidien Mallinckrodt, Embryon, Janssen Pharmaceutical, King Pharmaceuticals, KnowledgePoint360, KOL, Medtronic, MedXcel, Nektar Therapeutics, NeurogesX, Nevro Corporation, Pharmacofore, PharmaCom Group, ProStrakan, Purdue Pharma LP, Synchrony
Research: Adolor, Alkermes, Allergan, Bayer Healthcare, Collegium Pharmaceuticals, Covidien, Elan Pharmaceuticals, King Pharmaceuticals, Medtronic, Shionogi USA, Theravance
Speaker: AstraZeneca, BioDelivery Sciences International, Boston Scientific, Cephalon, Covidien Mallinckrodt, Embryon, Janssen Pharmaceutical, King Pharmaceuticals, KnowledgePoint360, KOL, Medtronic, MedXcel, Nektar Therapeutics, NeurogesX, Nevro Corporation, Pharmacofore, PharmaCom Group, ProStrakan, Purdue Pharma LP, Synchrony

Sean M. Gregory, PhD, hereby states that he or his spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following PIM planners and managers, Jan Hixon, RN, BSN, MA, Trace Hutchison, PharmD, Julia Kimball, RN, BSN, Samantha Mattiucci, PharmD, Jan Schultz, RN, MSN, CCMEP, and Patricia Staples, MSN, NP-C, CCRN hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Method of Participation

There are no fees for participating and receiving CME credit for these activities. During the period May 2011 through June 30, 2012 participants must read the learning objectives and faculty disclosures and study the educational activity of their choosing.

PIM supports Green CME by offering your Request for Credit online. If you wish to receive acknowledgment for completing either of these activities, please complete the post-test and evaluation on www.cmeuniversity.com. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by:

Webcast Activity
Course ID 7920

Monograph Activity
Course ID 7921

Upon registering and successfully completing a post-test with a score of 70% or better and the corresponding activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.

Media

Internet

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. PIM, Integrity Continuing Education, Inc., and King Pharmaceuticals, Inc., do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, Integrity Continuing Education, Inc., or King Pharmaceuticals, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

System Requirements

Windows 98, 2000, XP, 2003 and Vista
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10
Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10

Co-sponsored by Postgraduate Institute for Medicine and Integrity Continuing Education.

Supported by an educational grant from King Pharmaceuticals.